Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CYP4A22 antisense RNA 1 (CYP4A22-AS1)
- Target
- CYP4A22-AS1
- Molecular classification
- Other, long non-coding RNA/lncRNA
01
Overview
CYP4A22 antisense RNA 1 (CYP4A22-AS1, also called ncRNA-a3) is a long non-coding RNA (lncRNA) transcribed antisense to the CYP4A22 gene[1][4][6]. It does not encode a protein and is not a classical “target” such as a receptor, enzyme, or transporter. CYP4A22-AS1 is known to promote lung adenocarcinoma cell proliferation and metastasis by acting as a regulatory sponge for microRNAs miR-205-5p and miR-34c-5p, which are tumor suppressor miRNAs[1][5]. By downregulating these miRNAs, CYP4A22-AS1 increases the expression of genes such as EREG (Epiregulin, an EGFR ligand) and BCL-2 (an anti-apoptotic factor), activating oncogenic EGFR and anti-apoptotic pathways, as well as promoting EMT (epithelial-mesenchymal transition)[1][5]. Its high expression is correlated with a poorer prognosis in multiple cancers, but it is not currently the direct target of available drugs or experimental therapies[1][2][5].
- Other names
- CYP4A22-AS1ncRNA-a3
02
Mechanism of action
No approved drugs or therapeutics known to directly target CYP4A22-AS1
03
Biological functions
Regulation of gene expression (specifically acts as a competing endogenous RNA or “sponge” for microRNAs to modulate gene expression)Enhancement of cell proliferation and metastasis (in lung adenocarcinoma cells)Activation of anti-apoptotic and EMT pathways (Epithelial-Mesenchymal Transition)
04
Disease associations
Cancer (promotes lung adenocarcinoma progression)Reported association with colorectal cancer, gastric carcinoma, and papillary thyroid carcinoma prognosis
05
Biomarkers
Potential prognostic biomarker in lung adenocarcinoma, papillary thyroid carcinoma, colorectal and gastric cancer (due to associations with progression and survival)
Beyond the preview
Go deeper on CYP4A22 antisense RNA 1 (CYP4A22-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYP4A22 antisense RNA 1 (CYP4A22-AS1).